Ting Li

Therapy-Associated Myeloid Niches as Spatial Drivers of Cancer Treatment Resistance and Targets for Mechanism-Matched Intervention.

Tumor drug resistance is still the core obstacle limiting the long-term benefit of modern anticancer therapy, especially in the context of treatment tolerance, persistence of minimal residual disease (MRD) and recurrence after treatment. Increasing evidence has shown that therapy-associated myeloid niches can involve c...